Helex Raises $3.5 Million in Seed Round to Advance Non-Viral Gene Therapies for Kidney Diseases
NEW YORK–(BUSINESS WIRE)–Helex, a therapeutics company developing a new class of targeted medicines for genetic kidney diseases, today announced its oversubscribed $3.5 million Seed round, led by pi Ventures, with participation from Bluehill Capital, SOSV, and a global syndicate…